Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-06-14
2011-06-14
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S163000
Reexamination Certificate
active
07960436
ABSTRACT:
This invention provides compounds of formula Iwhere Ar1is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the —NR3R4group is situated ortho to the NHC(═X) group; n=1 or 2; X═O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof.These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders—such as seizure disorders—which are affected by modulation of potassium ion channels.
REFERENCES:
patent: 4181803 (1980-01-01), Morita et al.
patent: 4554281 (1985-11-01), vonBebenburg et al.
patent: 4668684 (1987-05-01), Tibes et al.
patent: 4778799 (1988-10-01), Tibes et al.
patent: 4923858 (1990-05-01), Engel et al.
patent: 4923974 (1990-05-01), Ueda et al.
patent: 5032591 (1991-07-01), Evans et al.
patent: 5162346 (1992-11-01), Lobisch et al.
patent: 5234947 (1993-08-01), Cherksey
patent: 5262419 (1993-11-01), Aberg et al.
patent: 5284861 (1994-02-01), Lobisch et al.
patent: 5384330 (1995-01-01), Dieter et al.
patent: 5428039 (1995-06-01), Cohen
patent: 5502058 (1996-03-01), Mayer et al.
patent: 5643921 (1997-07-01), Grover
patent: 5679706 (1997-10-01), D'Alonzo et al.
patent: 5760007 (1998-06-01), Shank
patent: 5800385 (1998-09-01), Demopulos et al.
patent: 5849789 (1998-12-01), Rostock et al.
patent: 5852053 (1998-12-01), Rostock et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5860950 (1999-01-01), Demopulos et al.
patent: 5914425 (1999-06-01), Meisel et al.
patent: 5925634 (1999-07-01), Olney
patent: 6117900 (2000-09-01), Rundfeldt et al.
patent: 6211171 (2001-04-01), Sawynok et al.
patent: 6218411 (2001-04-01), Koga
patent: 6265417 (2001-07-01), Carroll
patent: 6281211 (2001-08-01), Cai et al.
patent: 6326385 (2001-12-01), Wickenden et al.
patent: 6348486 (2002-02-01), Argentieri et al.
patent: 6395736 (2002-05-01), Parks et al.
patent: 6451857 (2002-09-01), Hurtt et al.
patent: 6469042 (2002-10-01), Hewawasam et al.
patent: 6472165 (2002-10-01), Rundfeldt et al.
patent: 6495550 (2002-12-01), McNaughton-Smith et al.
patent: 6500455 (2002-12-01), Frantsits
patent: 6537991 (2003-03-01), Shaw et al.
patent: 6538004 (2003-03-01), Drizin
patent: 6538151 (2003-03-01), Meisel et al.
patent: RE38115 (2003-05-01), Smith et al.
patent: 6589986 (2003-07-01), Bowlby et al.
patent: 6593335 (2003-07-01), Carroll
patent: 6642209 (2003-11-01), Fukunaga
patent: 6645521 (2003-11-01), Cassel
patent: 6737422 (2004-05-01), McNaughton-Smith et al.
patent: 7045551 (2006-05-01), Wu et al.
patent: 7160684 (2007-01-01), Argentieri et al.
patent: 7250511 (2007-07-01), Bavetsias
patent: 7309713 (2007-12-01), Rundfeldt et al.
patent: 7419981 (2008-09-01), Field et al.
patent: 2002/0013349 (2002-01-01), Wickenden
patent: 2002/0015730 (2002-02-01), Hoffmann et al.
patent: 2002/0183395 (2002-12-01), Argentieri
patent: 2004/0198724 (2004-10-01), McNaughton-Smith et al.
patent: 2005/0089473 (2005-04-01), Black et al.
patent: 2005/0089559 (2005-04-01), Szelenyi
patent: 2005/0090547 (2005-04-01), Szelenyi
patent: 2005/0202394 (2005-09-01), Dobson
patent: 2005/0277579 (2005-12-01), Krishnan et al.
patent: 2007/0066612 (2007-03-01), Khanzhin et al.
patent: 2542434 (2005-05-01), None
patent: 3337593 (1983-10-01), None
patent: 3604575 (1986-08-01), None
patent: 103 49 729.3 (2003-10-01), None
patent: 103 59 335 (2005-05-01), None
patent: 1 189 788 (1986-08-01), None
patent: 0 343 429 (1989-05-01), None
patent: 1 334 972 (2003-08-01), None
patent: 1 407 768 (2004-04-01), None
patent: 1 813 285 (2007-08-01), None
patent: 2000 14350 (2000-05-01), None
patent: 2000 143510 (2000-05-01), None
patent: 2006117525 (2005-12-01), None
patent: WO 00/55137 (2000-09-01), None
patent: WO 00/59487 (2000-10-01), None
patent: WO 00/59508 (2000-10-01), None
patent: WO 01/01970 (2001-01-01), None
patent: WO 01/01972 (2001-01-01), None
patent: WO 01/09612 (2001-02-01), None
patent: WO 01/22953 (2001-04-01), None
patent: WO 02/080898 (2002-10-01), None
patent: WO 03/020706 (2003-03-01), None
patent: WO 03/097586 (2003-11-01), None
patent: WO 03/106454 (2003-12-01), None
patent: WO 2004/058739 (2004-07-01), None
patent: WO 2004/080950 (2004-09-01), None
patent: WO 2004/082677 (2004-09-01), None
patent: WO 2004/096767 (2004-11-01), None
patent: WO 2004/105795 (2004-12-01), None
patent: WO 2005/039576 (2005-05-01), None
patent: WO 2005/048975 (2005-06-01), None
patent: WO 2005/087754 (2005-09-01), None
patent: WO 2005/100349 (2005-10-01), None
patent: WO 2006/029623 (2006-03-01), None
patent: WO 2006/092143 (2006-09-01), None
patent: WO 2008/024398 (2008-02-01), None
patent: WO 2008/066900 (2008-06-01), None
Wu et al, Toxicology, 236, (2007), pp. 1-6.
Wolf , Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1, 1995, pp. 975-977.
Biervert C. et al., “A Potassium Channel Mutation in Neonatal Human Epilepsy”,Science279:403-406 (1998).
Charlier C. et al., “A Pore Mutation in a Novel KQT-Like Potassium Channel Gene in an Idiopathic Epilepsy Family”,Nature Genetics18:53-55 (1998).
Singh N. A. et al., “A Novel Potassium Channel Gene,KCNQ2, is Mutated in an Inherited Epilepsy of Newborns”,Nature Genetics18:25-29 (1998).
Bialer M. et al., “Progress Report on New Antiepileptic Drugs: a Summary of the Fourth Eilat Conference (EILAT IV)”,Epilepsy Research34:1-41 (1999).
Rogawski M.A., “KCNQ2/KCNQ3 K+Channels and the Molecular Pathogenesis of Epilepsy: Implications for Therapy”,TINS23(9):393-398 (2000).
Wickenden A.D. et al., “Retigabine, a Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels”,Molecular Pharmacology58(3):591-600 (2000).
Main M.J. et al., “Modulation of KCNQ2/3 Potassium Channels by the Novel Anticonvulsant Retigabine”,Molecular Pharmacology58:253-262 (2000).
Blackburn-Munro G. et al., “The Anticonvulsant Retigabine Attenuates Nociceptive Behaviours in Rat Models of Persistent and Neuropathic Pain”,European Journal of Pharmacology460:109-116 (2003).
Wuttke T.V. et al., “The New Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to its Activation Gate”,Molecular Pharmacology67(4):1009-1017 (2005).
Armand et al., “Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices,”Naunyn-Schmiedeberg's Arch. Pharmacol. 359:33-39 (1999).
Armijo et al., “Ion channels and epilepsy,”Curr. Pharm. Des.11:1975-2003.
Barhanin, M., et al., “KvLQT1 and ISK (minK) proteins associate to form the IKscardiac potassium current,”Nature384(6604):78-80 (1996).
Beck et al., “Kreuzschmerzen in der Gynaekologischen praxis,” Ginaekologe, Springer Verlag, Berlin German 2002 35(5):490-494.
Beeby et al. “The synthesis and properties of 2:7-Disubstituted 1:2:3:4-tetrahydroisoquinolines,”J. Chem. Soc. 385:1799-1803 (1949).
Bialer, “Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII),”Epilepsy Res. 61:1-48 (2004).
Bialer, “Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI),”Epilepsy Res. 51:31-71 (2002).
Brown and Adams, “Muscarinic suppression of a novel voltage-sensitive K+current in a vertebrate neurone,”Nature283:673-676 (1980).
Brown, D.A.,Ion Channels, T. Narahashi, Ed. (Plenum Press, New York) pp. 55-94 (1988).
Cooper et al., “Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy.”Proc. Natl. Acad. Sci. U.S.A.97:4914-4919 (2000).
Delmas and Brown, “Pathways modulating neural KCNQ/M (Kv7) potassium channels,”Nat. Rev. Neurosci. 6:850-862 (2005).
Dickenson al., “Neurobiology of neuropathic pain:
Chen Huanming
Vernier Jean-Michel
Davis Zinna N
Jones Day
Valeant Pharmaceuticals International
LandOfFree
Substituted arylamino-1,2,3,4-tetrahydro naphthalenes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted arylamino-1,2,3,4-tetrahydro naphthalenes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted arylamino-1,2,3,4-tetrahydro naphthalenes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670389